Gain Therapeutics CFO Gianluca Fuggetta resigns Sept 30; CEO Gene Mack named interim CFO

Gain Therapeutics, Inc.

Gianluca Fuggetta, SVP of Finance and principal financial and accounting officer, notified the company on Sept 22, 2026 of his resignation effective Sept 30, 2026 to pursue other opportunities.
Board appointed President and CEO Gene Mack as interim CFO effective Oct 1, 2026; he will also assume principal financial officer and principal accounting officer duties.
Mack continues as President and CEO; the company said it is engaged in an ongoing search for a permanent replacement for the principal financial/accounting officer roles.
Mack's compensatory and other material employment terms remain unchanged in connection with the interim CFO appointment.
No arrangements or understandings between Mack and any other persons led to his selection, and no Item 404(a) related-party transactions were disclosed.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.